Dr. Andrés Cervantes Ruipérez

Investigador Principal
Grupo de Investigación en cáncer colorrectal y nuevos desarrollos terapéuticos en tumores sólidos

Presentación

El Dr. Andrés Cervantes es catedrático de Medicina en la Universidad de Valencia y Jefe del Servicio de Oncología Médica en el Hospital Clínico Universitario de Valencia. Su formación como Médico Interno Residente la llevó a cabo en el Hospital Clínico Universitario de Valencia. Tras completar este periodo consiguió una beca predoctoral en la Free University Hospital en Amsterdam, donde obtuvo su Doctorado en el laboratorio de farmacología celular, con un trabajo sobre la resistencia a múltiples fármacos.

También es director del Área de Cáncer en el Instituto de Investigación Sanitaria – INCLIVA. Sus principales áreas de interés e investigación son el cáncer gastrointestinal, así como ensayos fase I y de desarrollo de nuevos fármacos. Es investigador clínico de cáncer rectal, un tema en el que ha desarrollado varias publicaciones sobre la calidad del trabajo multidisciplinar así como la evaluación de la calidad de la cirugía mesorrectal, cómo optimizar la elección idónea de la terapia inicial y, especialmente, cómo tratar el cáncer del tercio superior del recto. Ha colaborado en la elaboración de guías clínicas internacionales y es coautor de estudios cooperativos internacionales que han modificado la práctica clínica. Su tema principal de trabajo actual es sobre la detección y análisis de la enfermedad mínima residual en cáncer de colon resecado con intención curativa a travéd de la detección de DNA circulante tumoral en plasma. Es autor de casi de 500 artículos y revisiones de trabajos publicados en diferentes revistas internacionales. Es también Editor de la revista Cancer Treatment Reviews. Es Presidente electo de ESMO (Sociedad Europea de Oncología Médica) y desde enero de 2014 también es Editor asociado, en la sección de cáncer gastrointestinal, en la revista de Annals of Oncology. Desde 2017 es director científico y general de INCLIVA.

Investigador
Principal
Dr. Andrés Cervantes Ruipérez

andres.cervantes@uv.es

Publicaciones
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: 10.1016/j.esmoop.2021.100237. PMID: 34411971

Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994. PMID: 33673558

Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: 10.3390/cancers13061433. PMID: 33801071

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: 10.1016/j.annonc.2021.04.001. PMID: 34090547

ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jun;6(3):100130. doi: 10.1016/j.esmoop.2021.100130. PMID: 34144776

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2021 Jul 3. doi: 10.1007/s00262-021-02973-w. PMID: 34216247

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004. PMID: 33798472

In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: 10.1016/j.esmoop.2021.100116. PMID: 33887688

In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: 10.1016/j.esmoop.2021.100247. PMID: 34411970

In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. Esmo Open. 2021 Jan 4;6(1):100009. doi: 10.1016/j.esmoop.2020.100009. PMID: 33399075

In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. Esmo Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602

In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: 10.1016/j.esmoop.2021.100186. PMID: 34098228

Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Jun 29;S0748-7983(21)00596-5. doi: 10.1016/j.ejso.2021.06.031. PMID: 34217579

Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: 10.1016/j.ctrv.2021.102263. PMID: 34343892

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May 24;S0923-7534(21)02019-6. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882

Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosellò S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Jun 10;S1533-0028(21)00052-9. doi: 10.1016/j.clcc.2021.06.002. PMID: 34226142

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. PMID: 33301740

Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J, Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: 10.1016/j.esmoop.2021.100148. PMID: 33989988

Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. Pellino G, Alós R, Biondo S, Codina-Cazador A, Enríquez-Navascues J, Espín-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: 10.1016/j.ejso.2020.04.056. PMID: 32950316

A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Delord J, Argiles G, Fayette J, Wirth L, Kasper S, Siena S, Mesia R, Berardi R, Cervantes Ruiperez A, Dekervel J, Zhao S, Sun Y, Hao H, Tiedt R, Vicente S, Myers A, Siu L. Investigational New Drugs. 2020 Dec;38(6):1774-1783. doi: 10.1007/s10637-020-00928-z. PMID: 32410080

Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. Smyth E, Cervantes Ruiperez A. Esmo Open. 2020 Nov;5(6):e001107. doi: 10.1136/esmoopen-2020-001107. PMID: 33208490

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. Isakoff S, Tabernero J, Molife L, Soria J, Cervantes Ruiperez A, Vogelzang N, Patel M, Hussain M, Baron A, Argiles G, Conkling R, Sampath D, Maslyar D, Patel P, Chan W, Gendreau S, Musib L, Xu N, Ma H, Lin K, Bendell J. Annals of Oncology. 2020 May;31(5):626-633. doi: 10.1016/j.annonc.2020.02.007. PMID: 32205017

Aurora kinases in ovarian cancer. Perez Fidalgo J, Gambardella V, Pineda Merlo B, Burgues Gasion O, Piñero Sanchez O, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718. PMID: 33087400

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. Pavlidis N, Peccatori F, Aapro M, Rolfo C, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Critical Reviews in Oncology Hematology. 2020 Feb;146:102798. doi: 10.1016/j.critrevonc.2019.07.022. PMID: 31918958

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2020 Apr 17. doi: 10.1007/s13187-020-01744-y. PMID: 32303982

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial (vol 147, pg 75, 2020). van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot Derk JA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:e1. doi: 10.1016/j.radonc.2020.06.006. PMID: 32564889

Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial. van der Valk MJM, Marijnen CAM, van Etten B, Dijkstra EA, Hilling DE, Kranenbarg EM, Putter H, Roodvoets AGH, Bahadoer RR, Fokstuen T, ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, de Groot DJA, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP. Radiotherapy and Oncology. 2020 Jun;147:75-83. doi: 10.1016/j.radonc.2020.03.011. PMID: 32240909

Computational evaluation and in vitro validation of new Epidermal Growth Factor Receptor inhibitors. Gomez-Ganau S, Castillo Aliaga J, Cervantes Ruiperez A, de Julian Ortiz J, Gozalbes R. Current Topics in Medicinal Chemistry. 2020;20(18):1628-1639. doi: 10.2174/1568026620666200603122726. PMID: 32493189

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. Tarazona Llavero N, Gimeno Valiente F, Gambardella V, Huerta Alvaro M, Roselló Keränen S, Zúñiga Trejos S, Calon A, Carbonell Asins J, Fontana E, Martínez Ciarpaglini M, Eason K, Rentero Garrido P, Fleitas Kanonnikoff T, Papaccio F, Moro Valdezate D, Nyamundanda G, Castillo Aliaga J, Espí Macias A, Sadanandam A, Roda Perez D, Cervantes Ruiperez A. Esmo Open. 2020 Sep;5(5):e000847. doi: 10.1136/esmoopen-2020-000847. PMID: 32967918

Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times. Cervantes Ruiperez A. Esmo Open. 2020 May;5(3):e000800. doi: 10.1136/esmoopen-2020-000800. PMID: 32366509

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg L, Gonzalez-Farre X, Cervantes Ruiperez A, Bidard F, Gorelick A, Lanman R, Nagy R, Ulaner G, Chandarlapaty S, Jhaveri K, Gavrila E, Zimel C, Selcuklu S, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli L, Dujka M, Lalani A, Bryce R, Baselga J, Taylor B, Solit D, Meric-Bernstam F, Hyman D. Cancer Discovery. 2020 Feb;10(2):198-213. doi: 10.1158/2159-8290.CD-19-0966. PMID: 31806627

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. Gimeno Valiente F, Riffo Campos Á, Ayala Gallego G, Tarazona Llavero N, Gambardella V, Rodriguez F, Huerta Alvaro M, Martínez Ciarpaglini M, Monton Bueno J, Roselló Keränen S, Roda Perez D, Cervantes Ruiperez A, Franco Vera L, Lopez Rodas G, Castillo Aliaga J. Scientific Reports. 2020 Feb 28;10(1):3723. doi: 10.1038/s41598-020-60476-7. PMID: 32111877

How we treat metastatic colorectal cáncer. De Falco V, Napolitano S, Rosello S, Huerta M, Cervantes A, Ciardiello F, Troiani T. Esmo Open. 2020 Aug;4(Suppl 2):e000813. doi: 10.1136/esmoopen-2020-000813. PMID: 32817137

Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. Baguena G, Pellino G, Frasson M, Escrig J, Marinello F, Espí Macias A, Garcia-Granero A, Roselló Keränen S, Cervantes Ruiperez A, Garcia-Granero E. Gastroenterologia y Hepatologia. 2020 Feb;43(2):63-72. doi: 10.1016/j.gastrohep.2019.07.005. PMID: 31918857

In the literature: April 2020. Gambardella V, Roda D, Tarazona N, Cervantes A. Esmo Open. 2020 Apr;5(2):e000749. doi: 10.1136/esmoopen-2020-000749. PMID: 32317263

In the literature: August 2020. Gambardella V, Cejalvo J, Tarazona N, Cervantes A. Esmo Open. 2020 Aug;5(4):e000909. doi: 10.1136/esmoopen-2020-000909. PMID: 32817070

In the literature: December 2019. Gambardella V, Insa A, Cejalvo J, Cervantes A. Esmo Open. 2020 Jan;5(1):e000642. doi: 10.1136/esmoopen-2019-000642. PMID: 31958287

In the literature: February 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. 2020 Feb;5(1):e000680. doi: 10.1136/esmoopen-2020-000680. PMID: 32079625

In the literature: June 2020. Roda D, Gambardella V, Cejalvo JM, Cervantes A. Esmo Open. 2020 Jul;5(4):e000832. doi: 10.1136/esmoopen-2020-000832. PMID: 32641355

In the literature: October 2020. Gambardella V, Bruixola Campos G, Alfaro Cervelló C, Cervantes Ruiperez A. Esmo Open. 2020 Oct;5(5):e001048. doi: 10.1136/esmoopen-2020-001048. PMID: 33037034

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Yoshino T, Pentheroudakis G, Mishima S, Overman M, Yeh K, Baba E, Naito Y, Calvo F, Saxena A, Chen L, Takeda M, Cervantes Ruiperez A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard J. Annals of Oncology. 2020 Jul;31(7):861-872. doi: 10.1016/j.annonc.2020.03.299. PMID: 32272210

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus. Curigliano G, Banerjee S, Cervantes Ruiperez A, Garassino M, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels J, Michielin O, Peters S, Tabernero J, Douillard J, Pentheroudakis G, all Voting Panel members. Annals of Oncology. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. PMID: 32745693

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. Papaccio F, Rosello S, Huerta M, Gambardella V, Tarazona N, Fleitas T, Roda D, Cervantes A. Cancers. 2020 Dec 3;12(12):E3611. doi: 10.3390/cancers12123611. PMID: 33287114

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Rosello S, Pizzo C, Huerta M, Munoz E, Aliaga R, Vera A, Alfaro-Cervello C, Jorda E, Garces-Albir M, Roda D, Dorcaratto D, Tarazona N, Torondel S, Guijarro J, Sanchiz V, Gambardella V, Fleitas-Kanonnikoff T, Lluch P, Pascual I, Ferrandez A, Sabater L, Cervantes A. Esmo Open. 2020 Nov;5(6):e000929. doi: 10.1136/esmoopen-2020-000929. PMID: 33229503

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

Personalized Medicine: Recent Progress in Cancer Therapy. Gambardella V, Tarazona Llavero N, Cejalvo Andujar J, Lombardi P, Huerta Alvaro M, Roselló Keränen S, Fleitas Kanonnikoff T, Roda Perez D, Cervantes Ruiperez A. Cancers. 2020 Apr 19;12(4):1009. doi: 10.3390/cancers12041009. PMID: 32325878

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cáncer. Voss MH, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, Smith DC, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel MR, Neuwirth RL, Enke A, Shou Y, Sedarati F, Faller DV, Burris HA. British Journal of Cancer. 2020 Nov;123(11):1590-1598. doi: 10.1038/s41416-020-01041-x. PMID: 32913286

Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Gambardella V, Fleitas Kanonnikoff T, Tarazona Llavero N, Papaccio F, Huerta Alvaro M, Roselló Keränen S, Gimeno Valiente F, Roda Perez D, Cervantes Ruiperez A. Journal of Clinical Medicine. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. Valentini V, Marijnen C, Beets G, Bujko K, De Bari B, Cervantes Ruiperez A, Chiloiro G, Coco C, Gambacorta M, Glynne-Jones R, Haustermans K, Meldolesi E, Peters F, Rodel C, Rutten H, van de Velde C, Aristei C. Radiotherapy and Oncology. 2020 Jan;142:6-16. doi: 10.1016/j.radonc.2019.07.001. PMID: 31431374

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). Bendell J, Sauri T, Cubillo Gracian A, Alvarez R, Lopez-Lopez C, Garcia-Alfonso P, Hussein M, Limon Miron M, Cervantes Ruiperez A, Montagut C, Santos Vivas C, Bessudo A, Plezia P, Moons V, Andel J, Bennouna J, van der Westhuizen A, Samuel L, Rossomanno S, Boetsch C, Lahr A, Franjkovic I, Heil F, Lechner K, Krieter O, Hurwitz H, McCAVE Study Grp. Oncologist. 2020 Mar;25(3):e451-e459. doi: 10.1634/theoncologist.2019-0291. PMID: 32162804

The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Gambardella V, Castillo Aliaga J, Tarazona Llavero N, Gimeno Valiente F, Martínez Ciarpaglini M, Cabeza Segura M, Roselló Keränen S, Roda Perez D, Huerta Alvaro M, Cervantes Ruiperez A, Fleitas Kanonnikoff T. Cancer Treatment Reviews. 2020 Jun;86:102015. doi: 10.1016/j.ctrv.2020.102015. PMID: 32248000

Trifluridine/Tipiracil in earlier lines of chemotherapy for advanced colorectal cancer. Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Sep;31(9):1097-1098. doi: 10.1016/j.annonc.2020.05.030. PMID: 32544547

A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cáncer. Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. Breast Cancer Research and Treatment. 2019 Nov;178(1):121-133. doi: 10.1007/s10549-019-05360-3. PMID: 31368034

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cáncer. Cejalvo Andujar J, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes Ruiperez A. Esmo Open. 2019 Jul 22;4(4):e000532. doi: 10.1136/esmoopen-2019-000532. PMID: 31423336

Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. Ragulan C, Eason K, Fontana E, Nyamundanda G, Tarazona N, Patil Y, Poudel P, Lawlor RT, Del Rio M, Koo SL, Tan WS, Sclafani F, Begum R, Teixeira Mendes LS, Martineau P, Scarpa A, Cervantes A, Tan IB8, Cunningham D, Sadanandam A. Scientific Reports. 2019 May 21;9(1):7665. doi: 10.1038/s41598-019-43492-0. PMID: 31113981

Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. Martínez Ciarpaglini M, Fleitas Kanonnikoff T, Gambardella V, Llorca Cardeñosa M, Mongort Sanchis M, Mengual Fenollar R, Nieto G, Navarro Cerveró L, Huerta Alvaro M, Roselló Keränen S, Roda Perez D, Tarazona Llavero N, Navarro Fos S, Ribas Despuig G, Cervantes Ruiperez A. Esmo Open. 2019 May 27;4(3):e000470. doi: 10.1136/esmoopen-2018-000470. PMID: 31231566

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Lancet Oncology. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. PMID: 31003911

Combination of KIR2DS4 and Fc gamma RII alpha polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (vol 9, 2589, 2019). Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. PMID: 31097738

Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cáncer. Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Scientific Reports. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. PMID: 30796344

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. Fontana E, Eason K, Cervantes A, Salazar R, Sadanandam A. Annals of oncology. 2019 Apr 1;30(4):520-527. doi: 10.1093/annonc/mdz052. PMID: 30796810

Definition of the Rectum: An International, Expert-based Delphi Consensus. DʼSouza N, de Neree Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Glimelius B, Lacy A, Cervantes A, Glynne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, Moran B, Tekkis P, Rutten HJ, Tanis PJ, Wiggers T, Brown G. Annals of Surgery. 2019 Dec;270(6):955-959. doi: 10.1097/SLA.0000000000003251. PMID: 30973385

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. Lordick F, Obermannova R, Vola D, Douillard J, Mcgregor K, Van Cutsem E, Tabernero J, Ciardiello F, Cervantes Ruiperez A. Esmo Open. 2019 Jul 5;4(3):e000533. doi: 10.1136/esmoopen-2019-000533. PMID: 31354964

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cáncer. Cardone C, Martinelli E, Troiani T, Sforza V, Avallone A, Nappi A, Montesarchio V, Andreozzi F, Biglietto M, Calabrese F, Bordonaro R, Cordio S, Bregni G, Febbraro A, Garcia-Carbonero R, Feliu J, Cervantes Ruiperez A, Ciardiello F. Esmo Open. 2019 Aug 16;4(4):e000519. doi: 10.1136/esmoopen-2019-000519. PMID: 31555481

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ; ICON7 investigators. Gynecologic Oncology. 2019 Jan;152(1):53-60. doi: 10.1016/j.ygyno.2018.08.036. PMID: 30449719

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Improving tumor budding evaluation in colon cancer by extending the assessment area in colectomy specimen. Martinez-Ciarpaglini C, Fernandez-Sellers C, Tarazona N, Roselló S, Huerta M, Roda D, Mongort C, Ferrández A, Navarro S, Cervantes A. Histopathology. 2019 Oct;75(4):517-525. doi: 10.1111/his.13900. PMID: 31081121

In the literature: August 2018. Gambardella V, Bruixola Campos G, Papaccio F, Cejalvo Andujar J, Cervantes Ruiperez A. Esmo Open. 2019 Jul 21;4(4):e000563. doi: 10.1136/esmoopen-2019-000563. PMID: 31423340

In the literature: February 2019. Insa Molla A, Gambardella V, Cervantes Ruiperez A. Esmo Open. 2019 Feb 13;4(1):e000490. doi: 10.1136/esmoopen-2019-000490. PMID: 30962957

Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. Martinez-Ciarpaglini C, Oltra S, Roselló S, Roda D, Mongort C, Carrasco F, Gonzalez J, Santonja F, Tarazona N, Huerta M, Espí A, Ribas G, Ferrández A, Navarro S, Cervantes A. Modern Pathology. 2019 Feb;32(2):306-313. doi: 10.1038/s41379-018-0124-5. PMID: 30206410

Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. Fleitas-Kanonnikoff T, Martinez-Ciarpaglini C, Ayala J, Gauna C, Denis R, Yoffe I, Sforza S, Martínez MT, Pomata A, Ibarrola-Villava M, Arevshatyan S, Burriel V, Boscá D, Pastor O, Ferrer-Martinez A, Carrasco F, Mongort C, Navarro S, Ribas G, Cervantes A. Cancer Medicine. 2019 Jun;8(6):3120-3130. doi: 10.1002/cam4.2191. PMID: 31059199

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, Spira A, Gonzalez M, Zhong B, Santiago-Walker A, Poggesi I, Parekh T, Xie H, Infante J, Tabernero J. Clinical Cancer Research. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. PMID: 31088831

NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2 -Amplified Gastric Cancer. Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T, Tolosa P, Cejalvo JM, Huerta M, Roselló S, Castillo J, Cervantes A. Clinical Cancer Research. 2019 Mar 1;25(5):1639-1649. doi: 10.1158/1078-0432.CCR-18-242. PMID: 30504425

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cáncer. Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J. European Journal of Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. PMID: 30889492

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Clinical Cancer Research. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740.PMID: 30770348

Preclinical models for precision oncology (vol 1870, pg 239, 2018). Ibarrola-Villava M, Cervantes A, Bardelli A. Biochimica et Biophysica Acta-Reviews on Cancer. 2019 Dec;1872(2):188292. doi: 10.1016/j.bbcan.2019.05.002. PMID: 31138435

Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. Baguena G1, Pellino G1, Frasson M1, Roselló S2, Cervantes A2, García-Granero A1, Giner F3, García-Granero E. Diseases of the Colon & Rectum. 2019 Jun;62(6):684-693. doi: 10.1097/DCR.0000000000001367. PMID: 30839315

Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Ducreux M, Petersen LN, Öhler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, Cervantes A, O’Connor JM, Falcone A; CORRELATE Investigators. European Journal of Cancer. 2019 Dec;123:146-154. doi: 10.1016/j.ejca.2019.09.015. PMID: 31698328

Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A. Annals of Oncology. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390. PMID: 31562764

The Medical Oncology resident mentor: situation and workload. Elez E, Quintanar T, Bosch-Barrera J, Corral J, Lainez N, Moreno V, Rodriguez CA, Gonzalez-Flores E, Cervantes A. Clinical & Translational Oncology. 2019 Mar;21(3):304-313. doi: 10.1007/s12094-018-1923-3. PMID: 30062521

Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. Gambardella V, Fleitas T, Tarazona N, Cejalvo JM, Gimeno-Valiente F, Martinez-Ciarpaglini C, Huerta M, Roselló S, Castillo J, Roda D, Cervantes A. Annals of Oncology. 2019 Aug 1;30(8):1254-1264. doi: 10.1093/annonc/mdz143. PMID: 31046106

Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cáncer. Gambardella V, Fleitas T, Cervantes A. Annals of Oncology. 2019 Mar 1;30(3):351-352. doi: 10.1093/annonc/mdz008. PMID: 30657856

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations. Roda D, Roselló S, Cervantes A. Annals of Oncology. 2019 Sep 1;30(9):1409-1410. doi: 10.1093/annonc/mdz229. PMID: 31350557

ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. Gimeno-Valiente F, Riffo-Campos ÁL, Vallet-Sánchez A, Siscar-Lewin S, Gambardella V, Tarazona N, Cervantes A, Franco L, Castillo J, López-Rodas G. Scientific Reports. 2019 Jun 27;9(1):9339. doi: 10.1038/s41598-019-45411-9. PMID: 31249328

Proyectos
Referencia: ICI20/00009
Título: Investigación Clínica Independiente
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2024
Presupuesto: 1.039.970 €

Referencia: PT20/00100
Título: Plataforma de Investigación Clínica
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2021 – 2023
Presupuesto: 199.650 €

Referencia: 825832 – LEGACy
Título: CeLac and European consortium for a personalized medicine approach to Gastric Cancer
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2019 – 2022
Presupuesto: €3.577.431,27 (INCLIVA: €638.315)

Referencia: PI18/01909
Título: Medicina personalizada en pacientes con cáncer colorrectal localizado: abordaje multiómico de la Enfermedad Mínima Residual en biopsia líquida y modelos de organoides
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez, Desamparados Roda
Duración: 2019 – 2021
Presupuesto: 141.570 €

Referencia: PT17/0017/0003
Título: Clinical Research and Trials Platform
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2018 – 2021
Presupuesto: 266.475 €

Referencia: CB16/12/00473
Título: CIBER Oncología
Entidad Financiadora: Instituto de Salud Carlos III – Cofinanciado FEDER
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2017 –
Presupuesto:

Referencia: AC15/00096
Título: Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics
Entidad Financiadora: European Commission (Programación conjunta internacional ISCIII)
Investigador principal: Andrés Cervantes Ruipérez
Duración: 2016 – 2020
Presupuesto: 29.645 €

+ Información
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. PMID: 30715202

Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. PMID: 31378807

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. PMID: 32067677

New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Roselló Keränen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: 10.1016/j.annonc.2020.07.012. PMID: 32710931

Título: Study of the epi-/genomic dysregulation of breast cancer in women under 35 years and evaluation of cellular models
Doctorando: Oltra Sanchis, Sara
Director: Ribas Despuig, Gloria; Lluch Hernández, Ana
Fecha: 18/01/2019
Universidad: Universitat de València

Título: Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer
Doctorando: Llorca Cardeñosa, Marta Jessica
Director: Cervantes Ruipérez, Andrés; Ribas Despuig, Gloria
Fecha: 22/07/2019
Universidad: Universitat de València

Título: A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer
Doctorando: Tarazona Llavero, Noelia
Director: Cervantes Ruipérez, Andrés
Fecha: 23/07/2019
Universidad: Universitat de València

Título: Role of EDPR1 and the ZNF518B factor in the development of colorectal cancer
Doctorando: Gimeno Valiente, Francisco
Director: Castillo Aliaga, Josefa; López Rodas, Gerardo; Franco Vera Luis
Fecha: 03/12/2019
Universidad: Universitat de València